TG Therapeutics (NASDAQ:TGTX) Announces Quarterly Earnings Results

TG Therapeutics (NASDAQ:TGTX - Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16), Zacks reports. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. During the same period in the previous year, the business posted ($0.07) earnings per share. The business's revenue for the quarter was up 90.4% compared to the same quarter last year.

TG Therapeutics Trading Down 0.6 %

Shares of TGTX stock traded down $0.22 during mid-day trading on Friday, hitting $33.64. The company's stock had a trading volume of 2,237,034 shares, compared to its average volume of 3,018,948. The company has a market cap of $5.34 billion, a PE ratio of -336.37 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company's fifty day simple moving average is $38.90 and its 200-day simple moving average is $33.56. TG Therapeutics has a 52 week low of $15.16 and a 52 week high of $46.48.

Wall Street Analysts Forecast Growth

TGTX has been the topic of a number of research reports. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $40.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.